Transitional Care for Liver Disease
(TLC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new approach to assist people with advanced liver disease after hospital discharge. The goal is to determine if a special clinic, the Transitional Liver Clinic (TLC), can reduce hospital readmissions, enhance quality of life, and improve patient satisfaction with care. The TLC team will check in with patients shortly after discharge and provide additional support as needed. Suitable candidates have advanced liver disease, face challenges like fluid buildup or mental confusion, and are about to leave the hospital. As an unphased trial, this study offers patients a unique opportunity to receive personalized support and potentially improve their quality of life post-hospitalization.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that the Transitional Liver Clinic (TLC) is safe for patients with advanced liver disease?
Research shows that the Transitional Liver Clinic (TLC) effectively supports patients with liver disease after hospital discharge. Studies have found that patients visiting a TLC are less likely to return to the hospital within 30 days, indicating the care model's effectiveness during a crucial time.
The TLC provides follow-up care led by healthcare professionals such as nurse practitioners or physician assistants. This care is manageable for patients, as it doesn't involve new medications or invasive procedures. Instead, it focuses on advice and monitoring to help manage ongoing health needs.
Since the TLC model aims to improve post-hospital care, no specific side effects or negative events are linked to the program itself. It uses existing resources more effectively to enhance patient outcomes. Overall, research supports the TLC's safety and potential benefits for patients transitioning from hospital to home care.12345Why are researchers excited about this trial?
Researchers are excited about the Transitional Liver Clinic (TLC) approach because it offers a proactive and personalized follow-up care system for patients recently discharged with liver disease. Unlike traditional treatment options that rely on standard follow-up visits with usual providers, TLC ensures patients receive a phone call from specialized staff within two business days of discharge and an in-person or telehealth visit with a hepatology specialist within 14 days. This tailored approach aims to address individual patient needs more effectively during the crucial 30-day transitional period, potentially reducing readmission rates and improving overall patient outcomes.
What evidence suggests that the Transitional Liver Clinic (TLC) is effective for reducing hospital re-admissions in liver disease patients?
This trial will compare the Transitional Liver Clinic (TLC) with standard care. Studies have shown that the TLC can help reduce hospital readmissions for patients with liver disease. Specifically, patients who visit a TLC have fewer hospital readmissions within 30 days. A similar program led by nurse practitioners also effectively lowers the risk of returning to the hospital. These findings suggest that the TLC model may improve outcomes for people with advanced liver disease by providing extra support after hospital discharge.26789
Who Is on the Research Team?
Eric Orman, MD
Principal Investigator
Indiana University
Are You a Good Fit for This Trial?
This trial is for adults over 18 with advanced liver disease, either cirrhosis or acute alcoholic hepatitis. Participants must have had a recent complication from their condition and be ready to leave the hospital soon. They need to speak English or Spanish, be able to follow up after discharge, and not be in hospice care or listed for a liver transplant with a high MELD-Na score.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Control Phase
Participants receive usual care during the initial 9-month enrollment interval
Transitional Liver Clinic (TLC) Phase
Participants receive a phone call from TLC staff within 2 business days of discharge followed by an in-person or video telehealth clinic visit within 14 days of discharge. Additional care is provided based on individual patient needs during the 30-day transitional period.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Transitional Liver Clinic (TLC)
Trial Overview
The study tests the Transitional Liver Clinic (TLC), aiming to reduce hospital readmissions and improve quality of life for patients after they're discharged. TLC provides specialized post-discharge care tailored for individuals recovering from complications associated with advanced liver disease.
How Is the Trial Designed?
2
Treatment groups
Active Control
Enrolled patients discharged during the experimental TLC intervention implementation period will receive a phone call from TLC staff within 2 business days of discharge followed by an in-person or video telehealth clinic visit with a hepatology APP within 14 days of discharge. TLC staff will provide additional care based on individual patient needs during the 30-day transitional period.
Patients in the usual care arm will receive standard follow-up care from their usual providers based on recommendations made by inpatient providers at the time of discharge from the hospital.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Indiana University
Lead Sponsor
Eric Orman
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Published Research Related to This Trial
Citations
Nurse Practitioner-Led Transitional Care for Liver Disease
A nurse practitioner-led transitional care program could be effective in reducing the risk of readmission for patients with liver disease.
2.
clinicaltrials.gov
clinicaltrials.gov/study/NCT05733832?term=AREA%5BBasicSearch%5D(TLC%20clinic)&rank=3A Trial of Post-Discharge Transitional Care for Patients ...
This proposal aims to examine the effect of a transitional care model, The Transitional Liver Clinic ( TLC ), in reducing hospital re-admissions, improving ...
Attendance at a Transitional Liver Clinic May Be ...
Patients with liver disease seen in a PA-led TLC may have a significant reduction in the 30-day readmission rate. Randomized trials are needed to establish the ...
Attendance at a Transitional Liver Clinic May Be ...
Patients with liver disease seen in a PA-led TLC may have a significant reduction in the 30-day readmission rate. Randomized trials are needed ...
Evaluation of a nurse practitioner-led post-discharge ...
Conclusions A nurse practitioner-led transitional care program could be effective in reducing the risk of readmission for patients with liver disease. Future ...
A Trial of Post-Discharge Transitional Care for Patients ...
This proposal aims to examine the effect of a transitional care model, The Transitional Liver Clinic (TLC), in reducing hospital re-admissions, improving ...
Attendance at a Transitional Liver Clinic May Be ...
Patients with liver disease seen in a PA-led TLC may have a significant reduction in the 30-day readmission rate.
A POST-DISCHARGE TRANSITION CLINIC FOR ...
Of these, 120 (20%) were seen in TC after a mean of 13 days (SD 9) following discharge, with 75% of TC visits occurring within 14 days. Patients seen in TC were ...
Effectiveness of transitional care interventions in patients with ...
Transitional care interventions can improve quality of life and symptoms, although based on low or very low certainty of evidence.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.